The US companies Moderna and Merck (MSD outside the US and Canada) have announced this week the results of their phase 2b trials of their skin cancer therapy. The results were shared in a press release stating that the risk of recurrence or death is reduced by 44%.
An experimental malaria vaccine has shown protection for at least six months, according to a clinical trial in 112 adults in Burkina Faso. The results are published today in the journal Science Translational Medicine.
A study published in the journal Science reports preclinical results of a new vaccine model that is intended to work against all types of influenza. The prototype, which uses mRNA-based technology, includes antigens from all 20 known influenza subtypes.
A study has found a link between caesarean delivery and changes in the microbiome, as well as a reduced response to pneumococcal and meningococcal vaccines in children. The results are published in the journal Nature Communications.
A study published in the BMJ looks at the risk of thromboembolic events associated with different covid-19 vaccines, both adenovirus- and mRNA-based. Its results are based on data collected from more than 10 million adults in France, Germany, the Netherlands, Spain, the UK and the US who received at least one dose of a covid-19 vaccine from December 2020 to mid-2021.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for the tetravalent dengue vaccine (live, attenuated) Takeda. The vaccine is intended to prevent disease caused by dengue virus serotypes 1, 2, 3 and 4 in people aged four years and older. Although an approved vaccine already exists, according to the EMA, this quadrivalent vaccine shows increased protection in children and people over 45 years of age.
During Pfizer's appearance before the European Parliament this week, a company executive responded to the question of whether "Pfizer's vaccine was tested to stop transmission of the virus (SARS-CoV-2) before going to market" by saying "no".
Research with 11 lactating women vaccinated against covid-19 has found small amounts of mRNA from the vaccine in breast milk, undetectable 48 hours later.
The new tailored doses against Omicron have arrived just in time for the upcoming autumn and winter wave. Although we do not know which variant will circulate in the coming months, these vaccines are safe and will help reduce transmission in what could be difficult months from a care pressure point of view.
Regulatory agencies in the US and Europe - the FDA and the EMA - have licensed vaccination against Omicron focusing on different variants and sub-variants. Different procedures and studies in humans and animals have informed the agencies' decisions. Experts hope that these new doses will provide sufficient protection this autumn and winter to mitigate the impact of the next wave.